OTCPK:VYCO

Stock Analysis Report

Executive Summary

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe.

Snowflake

Fundamentals

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Vycor Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

VYCO

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-44.1%

VYCO

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: VYCO underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: VYCO underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

VYCOIndustryMarket
7 Day0%2.0%1.8%
30 Day-0.07%-1.8%-0.7%
90 Dayn/a-0.5%0.06%
1 Year-44.1%-44.1%14.2%13.3%9.7%7.3%
3 Year-45.0%-45.0%70.5%65.3%46.3%36.9%
5 Year-93.7%-93.7%127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Vycor Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Vycor Medical undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Vycor Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vycor Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VYCO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Vycor Medical regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Vycor Medical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vycor Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of VYCO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Vycor Medical's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Vycor Medical performed over the past 5 years?

20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VYCO is unprofitable, but has reduced losses over the past 5 years at a rate of 20.7% per year.

Accelerating Growth: Unable to compare VYCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VYCO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: VYCO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: VYCO is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VYCO is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Vycor Medical's financial position?


Financial Position Analysis

Short Term Liabilities: VYCO has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VYCO has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VYCO has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VYCO's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: VYCO has a high level of physical assets or inventory.

Debt Coverage by Assets: VYCO has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VYCO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VYCO has less than a year of cash runway if free cash flow continues to grow at historical rates of 36.7% each year.


Next Steps

Dividend

What is Vycor Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VYCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VYCO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VYCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VYCO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VYCO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Vycor Medical's salary, the management and board of directors tenure and is there insider trading?

9.6yrs

Average board tenure


CEO

Peter Zachariou (57yo)

5.8yrs

Tenure

0

Mr. Peter C. Zachariou has been the Chief Executive Officer at Vycor Medical Inc. since January 2, 2014. Mr. Zachariou has been Chairman, Chief Executive Officer, Treasurer and Secretary of Prima EastWest  ...


Board Age and Tenure

9.6yrs

Average Tenure

59yo

Average Age

Experienced Board: VYCO's board of directors are considered experienced (9.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Peter Zachariou (57yo)

    CEO & Director

    • Tenure: 5.8yrs
  • Adrian Liddell (60yo)

    Chairman

    • Tenure: 9.8yrs
  • David Cantor (53yo)

    President & Director

    • Tenure: 9.8yrs

Board Members

  • Peter Zachariou (57yo)

    CEO & Director

    • Tenure: 5.8yrs
  • Steve Girgenti (73yo)

    Independent Director

    • Tenure: 10.9yrs
  • Adrian Liddell (60yo)

    Chairman

    • Tenure: 9.8yrs
  • David Cantor (53yo)

    President & Director

    • Tenure: 9.8yrs
  • David Langer

    Member of Advisory Board

    • Tenure: 0yrs
  • Ezriel Kornel

    Member of Advisory Board

    • Tenure: 0yrs
  • Konstantin Slavin

    Member of Advisory Board

    • Tenure: 0yrs
  • Oscar Bronsther (58yo)

    Independent Director

    • Tenure: 7.9yrs
  • Lowell Rush (62yo)

    Independent Director

    • Tenure: 6.5yrs
    • Compensation: US$2.50k

Company Information

Vycor Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vycor Medical, Inc.
  • Ticker: VYCO
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$3.327m
  • Shares outstanding: 24.22m
  • Website: https://www.vycormedical.com

Number of Employees


Location

  • Vycor Medical, Inc.
  • 951 Broken Sound Boulevard
  • Suite 320
  • Boca Raton
  • Florida
  • 33487
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VYCOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDMar 2009

Biography

Vycor Medical, Inc. designs, develops, and markets neurological medical devices and therapies in the United States and Europe. The company provides non-invasive rehabilitation therapies for those who have  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:11
End of Day Share Price2019/09/30 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.